2019.03.05
I-Mab Biopharma Announces the Achievement of First Patient Dosing in Phase 1b/2a China Trial of TJ107 for Cancer and Chemotherapy-induced Lymphopenia
A Potential Global First-in-Class Long-Acting Recombinant IL-7 Immunotherapy.
2019.02.02
I-Mab Biopharma and Bio-Cancer Treatment International Announce Intention for Collaboration on Arginine Depletion Therapy and Biomarker Study, with Plans for I-Mab to Establish a Translational Medicin
collaboration to explore innovative biotherapeutics and biomarkers based on arginine metabolism in human malignancies and autoimmune disorders translational medicine lab to explore biomarkers for BCT's lead compound and I-Mab's own pipeline assets
2019.01.28
I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody
I-Mab Biopharma (“I-Mab”), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announces on Jan. 25, 2019 that its IND application for TJC4
2019.01.22
I-Mab Biopharma Receives U.S. FDA IND Clearance for Proprietary CD73 Antibody TJD5
SHANGHAI, China – January18, 2019 –I-Mab Biopharma (“I-Mab”), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced on January 18th, 2019
2018.12.24
I-Mab Receives U.S. FDA IND Approval for Proprietary Anti-GM-CSF Monoclonal Antibody TJM2
SHANGHAI, China, Dec. 24th, 2018 -- I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, today announces that the US Food and Drug Administration (FDA) has approved i...
2018.12.17
I-Mab and CSPC Pharma Announce Strategic Partnership for Long-acting GLP-1 Fc Program
I-Mab Biopharma (“I-Mab”), a China-based clinical stage biopharmaceutical company focused on the development of innovative biologics in immuno-oncology and autoimmune diseases and CSPC Pharmaceutical Group Co., Ltd. (CSPC)(01093.HK), a leading pharmaceutical group in China.
2018.11.29
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
I-Mab's Broad and Innovative Pipeline to Leverage TRACON's U.S. Product Development Solution Platform.
2018.11.16
MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys’s Novel Immuno-Oncology Agent MOR210
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (“I-Mab”), a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, jointly announced today that they have en...
2018.11.03
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy A Potential Global First-in-Class Long-Acting IL-7
SHANGHAI, Nov. 02, 2018 – I-MAB Biopharma Co., Ltd. ("I-Mab"), a Shanghai-based biotech company exclusively focused on innovative biologics in immuno-oncology and autoimmune diseases, and Genexine Inc. (KOSDAQ: 095700)...
2018.10.14
First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)
Oct 21, 2018, Shanghai, I-Mab Biopharma (“I-Mab”), a company focusing on innovative biologics in immuno-oncology and immuno-inflammation, today announced that the first patient in mainland China has been dosed in a phase II clinical trial of TJ301 for the treatment of ulcerative colitis (UC) at the ...